MBL follow-up flow assessment results among 85 individuals with MBL at baseline
| . | Categories . | No. of MBL individuals at baseline screen . | No. of those screened with MBL at last follow-up (n = 79) . |
|---|---|---|---|
| Sex | Male | 43 | 41 (95%) |
| Female | 42 | 38 (90%) | |
| MBL persistence: first screening, last screening | CLL-like/CLL-like | 71 | 65 |
| Atypical/atypical | 4 | 4 | |
| Atypical/CLL-like | 2 | 2 | |
| Non–CLL-like/non–CLL-like | 7 | 7 | |
| Non–CLL-like/CLL-like | 1 | 1 | |
| Age at last screening, y | Median (range) | 69 (46-96) | 70 (46-96) |
| Absolute B-cell count, cells per μL, at last flow (n = 73) | Median (range) | 214.2 (9.2-3452.7) | |
| Absolute clonal B-cell count, cells per μL, CLL-like (n = 105) | Median (range) | 39.7 (0.3-3392.7) | |
| Absolute clonal B-cell count, cells per μL, atypical | Median (range) | 27.8 (6.8-116.1) | |
| Absolute clonal B-cell count, cells per μL, non–CLL-like | Median (range) | 71.9 (10.7-848.5) |
| . | Categories . | No. of MBL individuals at baseline screen . | No. of those screened with MBL at last follow-up (n = 79) . |
|---|---|---|---|
| Sex | Male | 43 | 41 (95%) |
| Female | 42 | 38 (90%) | |
| MBL persistence: first screening, last screening | CLL-like/CLL-like | 71 | 65 |
| Atypical/atypical | 4 | 4 | |
| Atypical/CLL-like | 2 | 2 | |
| Non–CLL-like/non–CLL-like | 7 | 7 | |
| Non–CLL-like/CLL-like | 1 | 1 | |
| Age at last screening, y | Median (range) | 69 (46-96) | 70 (46-96) |
| Absolute B-cell count, cells per μL, at last flow (n = 73) | Median (range) | 214.2 (9.2-3452.7) | |
| Absolute clonal B-cell count, cells per μL, CLL-like (n = 105) | Median (range) | 39.7 (0.3-3392.7) | |
| Absolute clonal B-cell count, cells per μL, atypical | Median (range) | 27.8 (6.8-116.1) | |
| Absolute clonal B-cell count, cells per μL, non–CLL-like | Median (range) | 71.9 (10.7-848.5) |